Manifest by significant diminution in blood vessel area and blood vessel ECs in plaques of psoriasis, response to bevacizumab was significantly greater in patients with high levels of VEGF‐A in plasma/plaque skin and appeared to offer most treatment benefit to those with severe psoriasis. Here, VEGFA is linked to psoriasis.